Company intelligence / Profile preview

CircNova

Detroit, Michigan, United Statescircnova.com ↗

Ownership: Private
Development stage: Preclinical

Overview

CircNova is in the pre-clinical stage, leveraging its proprietary NovaEngine™ AI platform to generate and validate novel circular RNAs for therapeutic use. The company has not yet reported clinical results but is collaborating with academic partners to validate its molecules in wet lab settings.[1][3]

Therapeutic areas: OncologyRare DiseasesNeurology
Modalities: Circular RNA (circRNA)Non-coding RNA therapeutics[1][2][5]
Industry: Biotech

Partnerships

University of Michigan (academic collaboration/wet lab validation)[1](No major pharma partnerships publicly disclosed as of May 2025.)

Beyond the preview

Go deeper on CircNova.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CircNova.

Explore the full profile